Evidence map›Paper›PMID 41416032›Full record

ArticleThe Journal of clinical and aesthetic dermatology2025

Efficacy of a 2-MNG-Containing Serum and Sunscreen Regimen on Improving Facial Dyschromia in Women with Skin of Color.

Hawasatu Dumbuya, Andrew Alexis, Stephen Lynch, Valerie Callender, Seemal R Desai, Zoe Diana Draelos

Abstract read
In one paragraph

Article in The Journal of clinical and aesthetic dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Hawasatu DumbuyaDr. Dumbuya is with La Roche-Posay Laboratoire Dermatologique, L'Oreal USA in New York, New York.
Andrew AlexisDr. Alexis is with the Department of Dermatology at Weill Cornell Medicine in New York, New York.
Stephen LynchDr. Lynch is with L'Oréal USA Research and Innovation in Clark, New Jersey.
Valerie CallenderDr. Callender is with Callender Dermatology and Cosmetic Center in Glenn Dale, Maryland.
Seemal R DesaiDr. Desai is with Innovative Dermatology in Plano, Texas and the Department of Dermatology, The University of Texas Southwestern Medical Center in Dallas, Texas.
Zoe Diana DraelosDr. Draelos is with Dermatology Consulting Services, PLLC, High Point, North Carolina.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivePopulations with skin of color remain under-represented in dermatology clinical trials. Here, we first evaluated the efficacy of a serum and sunscreen regimen, containing 2-mercaptonicotinoyl glycine (2-MNG, Melasyl

methodsThis open-label study completed with 60 female participants, aged 25-70 years old, from diverse racial/ethnic backgrounds with skin phototypes IV-VI and presenting with mild to moderate hyperpigmentation and skin roughness. After completing a 1-week washout period, all participants used a 2-MNG-containing serum and sunscreen SPF30 regimen for 12 weeks. Evaluations included clinical assessments, quality of life questionnaires, plus imaging at several time points.

resultsAfter 2 weeks of treatment, dermatological assessments showed significant improvement in skin brightness and radiance in all participants. At Week 4, we observed significant reduction in dyschromia and hyperpigmentation. Expert grading and clinical imaging also demonstrated significant improvement in skin smoothness and pores appearances. By Week 12, all participants perceived a significant improvement in quality of life: from feeling less unattractive to decreasing the use of camouflage to cover up skin concerns. Lastly, skincare regimen was overall well tolerated by all participants. LIMITATIONS: This study evaluated the 2-MNG containing skincare regimen efficacy and did not specifically address the effectiveness of individual ingredients, nor include a comparison to a gold standard treatment.

conclusionOverall, our results demonstrate that a 2-MNG-containing serum and sunscreen SPF30 regimen effectively reduces the appearance of facial dyschromia, while improving skin texture and quality of life among women with skin of color.

Indexed as

dyschromiahyperpigmentationphotoprotectionskincareSkin of color

Identifiers

PMID41416032
PMCPMC12710987

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.